New Skin-Injection drug joins fight against head & neck cancer
NCT ID NCT07455032
Summary
This early-stage study is testing if adding an experimental drug called CADI-05 to a standard immunotherapy (pembrolizumab) can better prepare the immune system to fight head and neck cancer before surgery. The main goals are to check the safety of this combination and see if it helps shrink tumors. About 22 adults with a specific type of advanced but operable head and neck cancer will receive both drugs for 5 weeks, followed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.